Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients

Laura Mansi (1, 2) , Laurie Spehner (2) , Etienne Daguindau (2) , Kevin Bouiller (2, 3) , Hamadi Almotlak (2) , Ulrich Stein (4, 2) , Adeline Bouard (2) , Stefano Kim (2) , Elodie Klajer (2) , Marine Jary (5, 2) , Guillaume Meynard (2) , Angélique Vienot (2) , Charlée Nardin (2) , Fernando Bazan (2) , Quentin Lepiller (6, 2) , Virginie Westeel (2) , Olivier Adotévi (2) , Christophe Borg (1, 2) , Marie Kroemer (1, 2)

1 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
2 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
3 LCE - Laboratoire Chrono-environnement (UMR 6249)
4 Service d'Oncologie Médicale [CHRU Besançon]
5 Inserm CIC 1431 - Centre d'Investigation Clinique de Besançon
6 CEF2P / CARCINO - Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181)

Cancer patients are considered highly vulnerable to the COVID-19 pandemic. However, delaying cancer-specific therapies could have a deleterious effect on survival. The potential suppressive effects of chemotherapies or cancer-related microenvironment raised the question on how cancer patients' immune system responds to SARS-CoV-2 virus.

Mots clés: Cancer patients; Immune T cell response; SARS-CoV-2 antibodies; SARS-CoV-2 infection

Domaines: Médecine humaine et pathologie; Microbiologie et Parasitologie

Laura Mansi, Laurie Spehner, Etienne Daguindau, Kevin Bouiller, Hamadi Almotlak, et al.. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. European Journal of Cancer, 2021, 150, pp.1-9. ⟨10.1016/j.ejca.2021.03.033⟩. ⟨hal-03364202⟩